Seamlessly transition from Agilent Alissa Interpret genomic data analysis software to SeqOne Platform

Seamless transition from Agilent Alissa Interpret to SeqOne Platform

Discover SeqOne, the ultimate interpretation solution and Alissa Interpret alternative, compatible with Agilent wetlab!

Talk to our experts

Agilent’s genomic data interpretation software, Alissa Interpret, is slated for discontinuation in the future.

We know change can be unsettling, but at SeqOne, we’re here to make sure your transition is effortless. We’ve developed a plan that minimizes disruption to your genomic testing operations , by transitioning your genomic analysis to the proven, high performance SeqOne genomic analysis platform.

Why SeqOne is the right alternative to replace Alissa Interpret:

  • Ease of Deployment: Our user-friendly interface is designed for quick adaptation, saving you time and effort.
  • Data Compatibility: Seamlessly transfer your data from Alissa to SeqOne platform and keep performing your analysis. Your Alissa Interpret annotations data will seamlessly integrate with SeqOne, preserving your valuable work.
  • Comprehensive Variant Identification: SeqOne’s advanced algorithms ensure no critical mutations are overlooked.
  • Rapid Prioritization: Streamline your analysis with our software, providing tools to swiftly identify the most relevant mutations for each patient.
  • Certified Solution: SeqOne is a certified CE-IVD platform, but also HDS, ISO 27001 & ISO 13485, ensuring the highest standards of quality.

Your personalised Migration Plan

You have developed an efficient process for your lab and don’t want to start again from scratch. SeqOne has your back with a migration plan that minimises disruption and allows you to maintain your current laboratory workflow. Our migration plan includes:

Don’t wait – make the leap to SeqOne today for a future of uninterrupted, advanced genomic analysis. Learn more now about our NGS data analysis solution and AI-powered platform for quick variant prioritization and reporting.

Request your free demo

Genomic data interpretation workshop & lunch seminar in Graz

Discover how efficient annotation and pathogenicity classification of rare disease and cancer variants get you to a fast diagnostic result Graz Workshop

We will be hosting a workshop & lunch seminar about genomic data interpretation.

DATE: November 8th 2023 starting at 10:00, with lunch at 12:00

LOCATION: LKH-Univ. Klinikum Graz. Auenbruggerplatz 19. Seminarraum 224/2. Stock. 8036 Graz

Discover how efficient annotation and pathogenicity classification of rare disease and cancer variants get you to a fast diagnostic result!

  • Learn how to easily solve complex disease cases with a software data interpretation solution
  • Get an overview about the IVDR regulation’s impacts on the genomic data analysis
  • Bring your laptop and experience yourself the variant prioritization process on real genomic data with the SeqOne Platform

Fill out the form to register :

1ers Ateliers Nationaux de prescription et de rendu des tests génétiques en néphrologie adulte : une approche par la pratique

Participez à la 1ère journée « Ateliers Nationaux de prescription et de rendu des tests génétiques en néphrologie adulte : une approche par la pratique » en néphrologie adulte, organisée par Pr Laurent Mesnard le vendredi 15 septembre 2023.

L’objectif de cette journée est de proposer aux néphrologues adultes une vision globale de la prescription et du rendu des tests en fonction de leur propre écosystème clinique et de leurs besoins opérationnels. Compte tenu de l’importance des tests larges panels/exome/génome en néphrologie adulte, l’accent sera mis sur ces tests.

Cliquez sur le bouton ci-dessous pour vous inscrire en présentiel ou en ligne :

SeqOne at ESHG 2023: A.I. for Diagnostics

We will be hosting a corporate satellite on Monday, June 12, 2023 – 14.00 – 15.30 BST : “Harnessing AI to improve diagnostic yield with large-scale NGS data

Location: room Alsh 1, level 0.

During our seminar you will learn how our latest advances in Artificial Intelligence and genomics enable us to revolutionize the way you diagnose rare diseases. Our speakers will cover a range of topics, including exome sequencing, phenotyping, machine learning, and clinical validation.

Speakers:

  • Laurent Mesnard, Head of Nephrology, AP-HP Hospitals
  • Julien Thevenon, Professor of Genomics, Grenoble Hospital / interpretation coordinator of the French National Genomics program’s AURAGEN lab
  • Kevin Yauy, MD, Precision medicine & AI specialist, Clinician, Montpellier Hospital
  • Geoffroy Delplancq, Medical Geneticist, Versailles Hospital
  • Michaël Blum, Head of R&D, SeqOne Genomics

Download our white paper “SeqOneRank+: Supporting WES/WGS based clinical diagnosis with a variant-prioritization AI engine”

You will learn about :

  • SeqOneRank+: Our A.I. based (Machine Learning) approach combining molecular and clinical information to rank variants and classify them in ACMG classes.
  • A retrospective analysis based on 1016 exomes from a nephrology cohort, showing better sensitivity and specificity compared to Exomyser.
  • Use cases showing that SeqOneRank+ can find previously undiagnosed causal variants.
  • Improvements of phenotypic information by creating clusters of of synonym phenotypes based on an association matrix (OMIM, NCBI, PubMed, Orphanet).

Fill out the form below to receive it by email.

SeqOne’s program

Sunday, June 11th, 13:00-14:00 BST

  • Poster presentation 1: Clinical evaluation of a low-coverage whole-genome test for homologous recombination deficiency detection in ovarian cancer. Speaker: Céline Gottin
  • Poster presentation 2: Towards implementing Nanopore sequencing for routine molecular diagnosis of germline cancer predisposition. Speaker: Marie Mille

Monday, June 12th, 13:00-14:00 BST

  • Poster presentation 1: LoRID: a bioinformatic pipeline to discover alternative isoforms using nanopore long-read sequencing. Speaker: Nicolas Soirat
  • Poster presentation 2: SeqOne rank+, a machine learning model to rank genetic variants based on phenotypes and ACMG standards criteria. Speaker: Jiri Ruzicka
  • Poster presentation 3: DrugOrder: an automated method for ranking variant/drug associations using large panel of cancer genes. Speaker: Michaël Blum

Monday, June 12th, 14:00-15:30 BST

Corporate satellite: Harnessing AI to improve diagnostic yield with large-scale NGS data

Location: Room Alsh 1, level 0

Speakers:

  • Laurent Mesnard, Head of Nephrology, AP-HP Hospitals
  • Julien Thevenon, Professor of Genomics, Grenoble Hospital / interpretation coordinator of the French National Genomics program’s AURAGEN lab
  • Kevin Yauy, MD, Precision medicine & AI specialist, Clinician, Montpellier Hospital
  • Geoffroy Delplancq, Medical Geneticist, Versailles Hospital
  • Michaël Blum, Head of R&D, SeqOne Genomics

ESHG program

Learn about the full ESHG program: https://2023.eshg.org/programme-at-a-glance/

SeqOne’s new clinically validated HRD test reduces the number of inconclusive results to improve the prescription of targeted treatments for ovarian cancer patients

  • The Homologous Recombination Deficiency (HRD) biomarker identifies ovarian cancer patients likely to respond to PARP inhibitors.  
  • SeqOne’s test simplifies the deployment of this test while reducing the number of inconclusive results, even when biopsies have low tumoral content.  
  • Test accuracy was validated with the PAOLA-1 reference cohort and is presented at ESMO-GYNAE Barcelona on the 24th of February, 2023

Barcelona, Montpellier – February 22nd 2023:  SeqOne, the provider of new-generation genomic analysis solutions for personalized medicine, is announcing at the ESMO GYNAE conference a new HRD test that renders Homologous Recombination Deficiency (HRD) testing more accessible to Ovarian cancer patients. HRD status is key in the prescription of PARP inhibitor Olaparib, which improves survival of HRD-positive patients.

SeqOne’s approach simplifies the deployment of this test so that it can be performed by any well-equipped lab. To do this, SeqOne has based its test on a combination of two easily performed genomic analyses, a targeted gene panel and a low-pass whole genome, that together give excellent results when compared with reference tests.  The test has also been validated on multiple sequencers and reagents.  These results were clinically validated through a retrospective analysis of the PAOLA-1 cohort that was initially used to demonstrate the efficacy of Olaparib for HRD-positive patients. The cohort remains the gold standard for clinically validating all subsequent HRD tests. 

Another key focus was to ensure that actionable results could be obtained even with biopsies of low sample quality (low tumoral content),  as this has proved to be a major obstacle to delivering usable results in clinical routine environments.  SeqOne was able to deliver actionable HRD scores using samples of lower quality than most other tests; as little as 20% of cellularity and 50 nanograms of genetic material.  

One of ARCAGY-GINECO ’s missions is to allow the validation of HRD testing through clinical evaluation on the PAOLA-1 cohort and to offer the medical professionals a reliable and objective assessment of test performance “. Said Pr. Pujade Lauraine, Medical Director of ARCAGY-GINECO.SeqOne approached us early on in order to validate their test and have delivered a solution that is easy to implement and delivers great performance. I am glad that the clinical evaluation of their test is being presented today by my colleague Romain Boidot at ESMO GYNAE in Barcelona.”.

Our objective was to deliver an easy-to-use test that would work even with samples of low tumoral content while affording medical professionals the assurance of test quality through a recognized certification process” said Nicolas Philippe, CEO of SeqOne.  “I am proud that we have delivered on this objective”.

“As a user of SeqOne’s solution,  we are pleased with the ease of use, accuracy and its tolerance to samples of low-tumoral content” said Marie-Pierre Wissler, a pathologist working at Cypath“It means we can return an HRD status more often than we could with previous vendors while at the same time reducing turnaround time.”

Clinical evaluation of SeqOne HRD is presented at ESMO GYNAE, in Barcelona on Feb 24th, 2023, by Romain Boidot, molecular biologist at the Centre Régional de Lutte contre le Cancer Georges François Leclerc (CGFL) Dijon

The SeqOne HRD score was validated using a retrospective analysis of 364 ovarian cancer patients from the PAOLA-1 phase 3 clinical trial. There is the same survival benefit for HRD+ patients when being treated with olaparib plus bevacizumab compared to bevacizumab alone, regardless of whether SeqOne HRD or Myriad myChoice® CDx test was used to form the HRD subgroup. In addition, SeqOne HRD has a smaller rate of inconclusive results compared to the inconclusive rate obtained with Myriad myChoice® CDx. Additional analyses to evaluate the HRD biomarker have been conducted: (i) a replication analysis on 48 individuals to test the reproducibility of the BRCA variant calling approach and (ii) a comparison of HRD testing using either NovaSeq and NextSeq sequencers to perform sWGS. Both analyses confirm the robustness of the SeqOne test.

– ENDS –

About SeqOne Genomics
SeqOne Genomics specializes in high-performance genomic analysis solutions for use in healthcare and life science –  hospitals, research institutions, and pharmaceutical companies -. SeqOne’s mission is to make genomic analysis more accessible and effective, in order to improve treatments for patients suffering from cancer, rare and hereditary diseases as well as pharmaceutical companies developing new therapies. 

SeqOne’s platform supports both short-read and long-read nanopore sequencing and leverages advanced machine learning coupled with the company’s proprietary genomics operating system to dramatically reduce turnaround times and costs while delivering comprehensive and actionable insights for personalized medicine.  https://www.seqone.com/

SeqOne media contacts
– Annie-Florence Loyer – afloyer@newcap.fr / +33 (6) 88 20 35 59
– Jean-Marc Holder – jm.holder@seqone.com / +33 (6) 03 24 57 56

About Cypath
CYPATH is an independent medical practice bringing together 75 private doctors specialized in Pathological Anatomy and Cytology, associated in SELAS (private practice company by simplified action) grouped on thirteen sites located in Auvergne-Rhône-Alpes, Bourgogne-Franche-Comté and Grand-Est. The group collaborates with nearly 90 healthcare institutions and many private practices, general or specialized (Dermatology, Radiology, Gynecology, Midwives …). https://www.cypath.fr/


About ARCAGY
ARCAGY (Association de Recherche sur les CAncers dont GYnécologiques) is a French nonprofit organization that conducts clinical research on gynecologic cancers. The organization’s mission is to stimulate research on gynecologic cancers, as well as to provide support and information to patients and their families.

ARCAGY-GINECO” is a group of clinicians and medical sites in France focused on clinical research to fight gynecological cancers, including ovarian, endometrial, and cervical cancers. It is dedicated to promoting research, innovation, and clinical trials in the field of gynecological oncology, and to improving the care and treatment of patients with these types of cancers. For more information: https://www.arcagy.org/

SeqOne Genomics and the French Thrombotic MicroAngiopathies National reference center (CNR-MAT) pioneer the use of Oxford Nanopore sequencing technology to improve patient outcomes in kidney disease while reducing turnaround times

Montpellier, February 9th, 2023:  SeqOne today announced the results of a long-standing research collaboration with Pr. Laurent Mesnard, Co-Director of the French National center for Thrombotic MicroAngiopathies (CNR-MAT), aimed at improving the diagnosis and management of patients suspected of suffering from thrombotic microangiopathies and atypical Hemolytic syndrome (aHUS).  The program involved using Oxford Nanopore’s revolutionary technology to sequence patients at the bedside, dramatically reducing turnaround times to obtaining actionable insights.  Patients were sequenced using Oxford Nanopore’s adaptive sampling option that makes it possible to target the parts of the genome of interesr for thrombotic microangiopathies (TMAs) and modify the read-depth to explore in detail the regions that contain complex mutations that are hard to detect using standard methods.  This Oxford Nanopore-based analysis was compared with traditional short read sequencing approaches in order to establish a benchmark against current standards of care and hence quantify benefits of nanopore sequencing.  So far, the program, has analyzed 15 patients demonstrating the potential of the approach and highlighting the following benefits when compared with short-read sequencing;

  • Significantly faster turnaround times of under three days from sample collection to clinical report versus 3-4 week turnaround using outsourced short read sequencing
  • Reliable detection of complex variants such as those affecting alternative complement pathways that are often duplicated
  • Detection of certain types of variants, notably CFH:CFHR1 hybrid gene mutations that cannot be detected using traditional short-read technology
  • A clear indication of those patients who will respond to one of the drugs that have proven effective in treating this disease; vitamin B12 in Cobalamin III deficiency or Eculizumab in case of complement alternate pathway dysregulation associated aHUS. 

TMAs, such as aHUS, are rare diseases primarily affecting the kidney.  They are hard to diagnose using traditional methods as they present as a number of nonspecific symptoms, such as severe hypertension, acute kidney injury/failure in the context of mechanical anemia and thrombocytopenia. TMAs lesions can be associated with many diseases and some genetic disorders linked to aHUS. Molecular diagnoses, in particular in genes associated with alternative complement pathway regulation, make it possible to identify patients that suffer from this condition as well as informing on possible therapeutic options for TMA/aHUS.  

“It is clear that a cost effective, rapid technology that can sequence long fragments of DNA, such as those provided by Oxford Nanopore and a robust interpretation solution such as SeqOne are necessary to extract the full potential of third generation sequencing technology in nephrology and aHUS” said Pr. Laurent Mesnard, the PI heading the study. 

In order to support the program, SeqOne implemented an Oxford Nanopore compatible long-read support capable of managing adaptive sampling data.  SeqOne is a CE-IVD compliant platform that simplifies the analysis and interpretation of the data enabling the rapid interpretation of patient files which in turn maximizes efficiencies and enables management of higher caseloads.

“SeqOne is convinced both of the clinical potential of Oxford Nanopore’s technology as well as the benefits of bedside sequencing enabled by Oxford Nanopore’s hyper-cost-effective sequencing solutions” said Nicolas Philippe, CEO of SeqOne.  “We are investing heavily to provide the best interpretation solution for the data provided in support of this exciting initiative”. 

“We are delighted to be part of this research project and to see the potential of nanopore sequencing in nephrology and TMA/aHUS. The technology offers the chance to improve outcomes with significantly faster turnaround times and the ability to identify complex variants.” Commented Dr Emma Stanton, VP Clinical, Oxford Nanopore Technologies.

On the basis of this successful program, SeqOne and CNR-MAT now plan to extend its investigation of the use of nanopore sequencing technology to qualify further patients eligible to actionable (Vitamin B12, Eculizumab) therapy as well as to investigate the impact of other variant types in patient prognosis during TMA/aHUS. 

– Ends –

About SeqOne Genomics

SeqOne Genomics offers high-performance genomic analysis solutions for healthcare providers treating patients suffering from cancer, rare and hereditary diseases as well as pharmaceutical companies developing new therapies. The solution supports both short read and long-read nanopore sequencing and leverages advanced machine learning coupled with the company’s proprietary genomics operating system to dramatically reduce turnaround times and costs while delivering comprehensive and actionable insights for personalized medicine. The company has won numerous awards including the iLab award and the ARC cancer foundation’s Hélène Stark prize. Investors include Elaia, IRDI Capital Investissement, Merieux Equity Partners, Omnes and Software Club.

Web: https://seqone.com

SeqOne Contacts:

  • Annie-Florence Loyer – afloyer@newcap.fr / +33 6 88 20 3559
  • Jean-Marc Holder – jm.holder@seqone.com / + 33 6 03 24 5756

About the French Thrombotic Microangiopathies National reference centre (CNR-MAT)

The Thrombotic Microangiopathies National reference centre (CNR-MAT) is a research network focused on the study of thrombotic microangiopathies (MAT) and associated rare diseases. It was recognized 2006 as a national reference center for France under the stewardship of Paul Coppo (Hematology department, Saint-Antoine Hospital and Sorbonne-University) in Paris. The missions of the CNR-MAT are to promote clinical and basic research in the field of thrombotic microangiopathies through innovative medical approaches, as well as to inform practitioners, patients and all actors involved in the management of these diseases. The CNR-MAT coordinates the healthcare establishments treating patients suffering from these pathologies in France.

Web: https://www.cnr-mat.fr

CNR-MAT Contact:

  • Raida Bouzid Saadaoui – raida.bouzid-saadaoui@aphp.fr

About Oxford Nanopore Technologies

Oxford Nanopore Technologies’ goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology for real-time, high-performance, accessible and scalable analysis of DNA and RNA. The technology is used in more than 120 countries to understand the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses and whole environments. Oxford Nanopore Technologies products are intended for molecular biology applications and are not intended for diagnostic purposes. https://www.nanopore.com

Oxford Nanopore Technologies contact: media@nanoporetech.com 

Forward-looking statements 
This announcement contains certain forward-looking statements. Phrases such as “potential”, “expect”, “intend”, “believe we can”, “working to”, “anticipate”, “when validated”, and similar expressions of a future or forward-looking nature should also be considered forward-looking statements. Forward-looking statements address our expected future business, and by definition address matters that are, to different degrees, uncertain and may involve factors beyond our control.